← Leaderboards
Breanne Mackenzie
Lung Therapeutics, Inc.
$784,560
Attributed
$784,560
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $300.2K · FY2019–23$500K$375K$250K$125K$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$784,560 · 3
By mechanism
R43$784,560 · 3
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Novel Therapeutics”
- Leonard Freedman · Leidos Biomedical Research, Inc.$263,124,404
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
- Chris Karlovich · Leidos Biomedical Research, Inc.$38,534,220
Research focus
Novel TherapeuticsTherapeutic InterventionIn VitroMouse ModelPre-Clinical ModelSignal PathwayFormulationInjuryClinical TrialsLungPeptidesPowder Dose FormPulmonary FibrosisScaffoldCaveolin 1AttenuatedIdiopathic Pulmonary FibrosisInhalationBiochemicalAnimal ModelIn VivoLeadFibrosisToxicology
Grant awards (3)
The Development of CSD peptides for the therapeutic treatment of post-acute sequelae of COVID-19 (PACS)$259,332
R43 · FY2023 · HL · contact PI
DEVELOPMENT AND TESTING OF SUBCUTANEOUS CSD PEPTIDE FORMULATIONS FOR CHRONIC KIDNEY DISEASE$300,228
R43 · FY2020 · DK · contact PI
Caveolin-1 replacement therapy for the treatment of Idiopathic Pulmonary Fibrosis$225,000
R43 · FY2019 · HL · contact PI